


# GSK FY 2020 Results: Strong growth of new and specialty products; on track to deliver two exciting new companies



All % at constant exchange rates (CER)



**Strong performance from key growth drivers offset by disruption from COVID-19. New and specialty pharmaceuticals £9.7 billion, +12% CER**

Total group operating margin

**22.8%**

Adjusted group operating margin

**26.1%**

Total EPS

**115.5p** +26%

Adjusted EPS

**115.9p** -4%

**9** regulatory approvals in 2020

Dividend **80p**

“2020 was an extraordinary year for all of us, and one of significant progress for GSK. We invested in our pipeline and new launches, readied the company for separation, and had to rapidly mobilise and respond to the pandemic. I am extremely proud of the agility and resilience our teams have shown. We delivered our guidance for the year, offsetting the significant impact of COVID-19 on adult vaccinations, with strong performances of new products and effective cost control.”

**Emma Walmsley**  
CEO, GSK



Multiple myeloma cancer cell

Journalists/media see press release on [www.gsk.com](http://www.gsk.com) for full details on FY/Q4 2020.

Please read the cautionary statement regarding **forward-looking statements** and the definitions and reconciliations for non-IFRS measures on pages 63 to 65 of the press release.

\*Proforma growth: - 2%

\*\*Proforma growth: - 2%